… of response to ICIs is the tumor mutational burden (TMB), defined as the total number of
mutations per coding area of a tumor genome. Each tumor mutation within a cancer cell has the …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the …

… 85 (0.7%) of 11,662 LC had PD-L1amplification. Responses to PD-1/PD-L1 targeted therapies
and dependence on TMB will be presented. Conclusions: TMB was consistent across LC …

… Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR… PD-1/PD-L1
inhibitors. However, additional biomarkers are needed, and whether tumor mutation burden …

… to predict the response of PD-1/PD-L1 inhibitions. Tumor mutation burden (TMB) was … total
number of somatic mutations per megabase or the nonsynonymous mutations in tumor tissues…

… In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression
of an … the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC. …

… known to have increased associations with mutational burden across multiple tumor types.
Of these, 122 mutations were categorized as direct and 71 as indirect DNA repair mutations. …

… (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels.
We investigated oncogene-specific differences in these markers and clinical outcome. …

… were evaluated for PD-L1 expression, CD8 + T-cell infiltration pattern, mutational burden,
and 394 immune transcript expression. PD-L1 IHC and mutational burden were assessed for …

… with tumor mutation burden (TMB) and PD-L1 expression. … ) TMB, (B) PD-L1 CPS score, and
(C) PD-L1 TPS score in 588 … the PD-L1 CPS (D) (p = 0.014, R 2 = 0.081), but not with PD-L1 …